OBJECTIVE: Plasma phospholipid transfer protein (PLTP) is involved in the metabolism of HDL and apolipoprotein B (apoB)-containing lipoproteins. Atherosclerosis susceptibility is decreased in mice with PLTP deficiency that is associated with decreased liver production of apoB-containing lipoproteins and increase in their antioxidant. To investigate additionally the effect of PLTP on the development of atherosclerosis, we overexpressed PLTP in mice. METHODS AND RESULTS: PLTP was overexpressed in apoE knockout mice using an adenovirus-associated virus (AAV)-mediated system. Plasma PLTP activity was 1.3- to 2-fold higher in mice injected with AAV-PLTP than in mice injected with control AAV-GFP, and PLTP levels were sustained during the experiment period (4 months). We show that 2-fold increased PLTP activity results in (1) a decrease in HDL cholesterol, HDL phospholipid, and apoAI levels; (2) a decrease in vitamin E contents in total plasma and in individual lipoprotein fractions; (3) an increase in lipoprotein oxidizability as assessed by copper-induced formation of conjugated dienes; (4) an increase in autoantibodies against oxidized apoB-containing particles; and (5) an increase in atherosclerosis lesions in proximal aorta. CONCLUSIONS: These observations indicate that elevated plasma PLTP levels constitute a novel, long-term risk factor for atherosclerosis.
OBJECTIVE: Plasma phospholipid transfer protein (PLTP) is involved in the metabolism of HDL and apolipoprotein B (apoB)-containing lipoproteins. Atherosclerosis susceptibility is decreased in mice with PLTP deficiency that is associated with decreased liver production of apoB-containing lipoproteins and increase in their antioxidant. To investigate additionally the effect of PLTP on the development of atherosclerosis, we overexpressed PLTP in mice. METHODS AND RESULTS:PLTP was overexpressed in apoE knockout mice using an adenovirus-associated virus (AAV)-mediated system. Plasma PLTP activity was 1.3- to 2-fold higher in mice injected with AAV-PLTP than in mice injected with control AAV-GFP, and PLTP levels were sustained during the experiment period (4 months). We show that 2-fold increased PLTP activity results in (1) a decrease in HDL cholesterol, HDL phospholipid, and apoAI levels; (2) a decrease in vitamin E contents in total plasma and in individual lipoprotein fractions; (3) an increase in lipoprotein oxidizability as assessed by copper-induced formation of conjugated dienes; (4) an increase in autoantibodies against oxidized apoB-containing particles; and (5) an increase in atherosclerosis lesions in proximal aorta. CONCLUSIONS: These observations indicate that elevated plasma PLTP levels constitute a novel, long-term risk factor for atherosclerosis.
Authors: R de Vries; G M Dallinga-Thie; A J Smit; B H R Wolffenbuttel; A van Tol; R P F Dullaart Journal: Diabetologia Date: 2005-12-23 Impact factor: 10.122
Authors: Ailing Ji; Joanne M Wroblewski; Nancy R Webb; Deneys R van der Westhuyzen Journal: Arterioscler Thromb Vasc Biol Date: 2014-07-24 Impact factor: 8.311
Authors: Daniel Seung Kim; Amber A Burt; Jane E Ranchalis; Simona Vuletic; Tomas Vaisar; Wan-Fen Li; Elisabeth A Rosenthal; Weijiang Dong; Jason F Eintracht; Arno G Motulsky; John D Brunzell; John J Albers; Clement E Furlong; Gail P Jarvik Journal: J Lipid Res Date: 2015-05-25 Impact factor: 5.922
Authors: Elisabeth A Rosenthal; James Ronald; Joseph Rothstein; Ramakrishnan Rajagopalan; Jane Ranchalis; G Wolfbauer; John J Albers; John D Brunzell; Arno G Motulsky; Mark J Rieder; Deborah A Nickerson; Ellen M Wijsman; Gail P Jarvik Journal: J Lipid Res Date: 2011-07-13 Impact factor: 5.922
Authors: Robert S Rosenson; H Bryan Brewer; Philip J Barter; Johan L M Björkegren; M John Chapman; Daniel Gaudet; Daniel Seung Kim; Eric Niesor; Kerry-Anne Rye; Frank M Sacks; Jean-Claude Tardif; Robert A Hegele Journal: Nat Rev Cardiol Date: 2017-08-10 Impact factor: 32.419